GlassScriptPhysician profile
Leslie M Golden
NPI 1336401736
$102,562.49
in general payments reported to CMS, 2019-2025
9 companies · $101K in 2025
The $101K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.35 · 2022: $603 · 2023: $720 · 2024: $478 · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $18K · Travel and Lodging: $9,656 · Food and Beverage: $2,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,278.44 |
| Consulting Fee | $17,560.00 |
| Travel and Lodging | $9,656.12 |
| Food and Beverage | $2,442.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $65,063.15 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $30,361.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Currax Pharmaceuticals LLC | $4,800.00 | 2025 | Contrave |
| Eli Lilly and Company | $2,100.00 | 2025 | Zepbound |
| Kvk-Tech, INC. | $84.13 | 2025 | |
| Vivus LLC | $69.07 | 2022 | |
| Corcept Therapeutics | $44.05 | 2025 | Korlym |
| Sanofi Pasteur INC. | $22.35 | 2021 | |
| Abbott Laboratories | $18.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.